What’s new
OCB appoints James Otter as new CEO
Oxford, UK, 15th July 2019: Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth
Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity
Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to
PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership
Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP).
Dr Kevin Xu, Chief Software Engineer, speaks at Chongqing and Henan Universities, China.
30/May/19 Last Friday (May 24th) Dr Xu, our Chief Software Engineer, gave an academic report on “Diagnosis, Prognosis and Predicting Biomarkers of
Rebecca survived the toxic effects of 5-FU against the odds. This is her story, in her words.
We are grateful to Rebecca for writing this and for her participation in the continuous improvement in our ToxNav® panel.
OCB and Meridian IT video explains ColoProg advances
The following is a video that shows how OCB and Meridian IT worked together to extend the development of our
OCB’s ColoPredict provides an accurate colorectal cancer screening that patients can trust
In a time when genetic tests are as commercially available as Christmas presents, it is more important than ever to
Publication of Review of Technologies Related to Diagnosis and Treatment of Stage II Colororectal Cancers by Key OCB Staff
14th March 2019. OCB is proud to announce that an article on challenges and solutions in patient treatment strategies